Phase III study of CX-101 for smoking cessation
Latest Information Update: 27 Oct 2021
Price :
$35 *
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Currax Pharmaceuticals
- 27 Oct 2021 New trial record
- 21 Oct 2021 According to a Currax Pharmaceuticals media release, the company will support participants with both telephonic and mobile counseling.
- 21 Oct 2021 According to a Currax Pharmaceuticals media release, the company has a Type C written response meeting with the U.S. Food and Drug Administration ("FDA") regarding a New Drug Application for a Phase 3 program and it is builds on the successful Phase 2b findings.